{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-238850","form_type":"8-K/A","ticker":"DNTH","cik":"0001690585","company_name":"Dianthus Therapeutics, Inc. /DE/","filed_at":"2023-09-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.870225+00:00","generated_at":"2026-06-10T10:48:43.603378+00:00","sec_items":["2.02","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dianthus files OpCo historical financials; pro forma cash runway into Q2 2026","bullets":["OpCo net losses: $18.2M (H1 2023), $28.5M (FY2022), $13.1M (FY2021).","Pro forma combined cash sufficient to fund operations into Q2 2026 per risk factors.","Board classified: Class I (2025 AGM), Class II (2026 AGM), Class III (2024 AGM).","Shares outstanding as of 9/21/2023: 14,813,295.","Material weakness identified in internal control over financial reporting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-238850","json":"https://secwatch.observer/filing/0001193125-23-238850.json","markdown":"https://secwatch.observer/filing/0001193125-23-238850.md","text":"https://secwatch.observer/filing/0001193125-23-238850.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/d520077d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T10:48:43.603378+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2714141b86","claim":"Tomas Kiselak was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"5b33ae741a","claim":"Paula Soteropoulos was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"788a9950cf","claim":"Jonathan Violin, Ph.D. was appointed as Class II Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II Director"}],"fact_type":"executive_change"},{"claim_id":"8dc8298a2b","claim":"Lei Meng was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"},{"claim_id":"93f87d4647","claim":"Marino Garcia was appointed as Class I Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I Director"}],"fact_type":"executive_change"},{"claim_id":"d6290991c9","claim":"Leon O. Moulder, Jr. was appointed as Class III Director at Dianthus Therapeutics, Inc. /DE/.","evidence_excerpt":"As previously disclosed, on September 11, 2023, Marino Garcia and Paula Soteropoulos were appointed as Class I directors of the Board, Tomas Kiselak and Jonathan Violin, Ph.D., were appointed as Class II directors of the Board and Leon O. Moulder, Jr. and Lei Meng were appointed as Class III directors of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1690585/000119312523238850/0001193125-23-238850-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}